✨ Free AI Report
United Therapeutics Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research United Therapeutics Corporation
Company Research

United Therapeutics Corporation: Business Overview, Financials & Competitive Analysis

United Therapeutics is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. The company seeks to develop treatments for rare...

Analyst-debate audio for United Therapeutics Corporation

AskCyborg analysts argue the bull and bear cases for United Therapeutics Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Uniquely positioned biotech leader combining established pulmonary hypertension franchise with transformative organ transplant...

Read the full analyst-debate transcript →
Industry Biotechnology & Specialty Pharmaceuticals
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest United Therapeutics Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

United Therapeutics Corporation Overview

Pro stress-test →

United Therapeutics is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. The company seeks to develop treatments for rare, deadly diseases and was founded in 1996 by a family seeking a cure for their daughter's pulmonary arterial hypertension. The firm operates as a public benefit corporation with a dual mission of delivering pharmaceutical therapies and expanding organ transplant availability.

Strategic Profile

Pro stress-test →

Many of the company's products are focused towards lung disease and organ manufacturing. Key approved products include Orenitram, Remodulin, Tyvaso, and Tyvaso DPI for pulmonary arterial hypertension, with Tyvaso and Tyvaso DPI also indicated for pulmonary hypertension associated with interstitial lung disease. The pipeline includes gene therapy products like Aurora-GT and development-stage xenografts for organ replacement.

Competitive Landscape

Pro stress-test →

Key competitors in the specialty drug manufacturing space include Neurocrine Biosciences (market cap $13.7B), Alkermes (market cap $4.7B), and Kiniksa Pharmaceuticals. United Therapeutics maintains competitive differentiation through its exclusive focus on transplantation and rare lung diseases, combined with proprietary xenotransplantation technology that has limited competition in the organ replacement market.

Industry Context

United Therapeutics Corporation operates in Biotechnology & Specialty Pharmaceuticals.

Key facts

Founded: 1996 · Headquarters: Silver Spring, Maryland · Employees: 1,168 · Revenue: $2.8B · Market cap: $22.9B

What the analysts stress-tested

The top findings that survived the multi-agent debate for United Therapeutics Corporation.

  • Pioneering xenotransplantation leader with recent successful porcine heart and kidney transplants demonstrating clinical feasibility of organ replacement solutions
  • Established commercial platform with $2.8B+ annual revenue generated from four FDA-approved products for pulmonary hypertension treatment
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • 2024First successful transplant of xenokidney with ten gene edits; 500th lung transplant using UT's EVLP service
  • 2023Completed acquisition of Miromatrix Medical for bioengineered organs; FDA approved Tyvaso DPI for PAH and PH-ILD
  • +2 moreTrack every material event for United Therapeutics Corporation as it happens. Explore monitoring →
Get alerted when United Therapeutics Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pulmonary Hypertension TherapiesCompeting PAH treatments including ambrisentan→RevatioSildenafil for pulmonary arterial hypertension→Adcirca (tadalafil)Competing PAH therapy; partially licensed by UTHR→Organ Transplant TechnologiesBioengineered organ development; now acquired by UTHR→

Compare United Therapeutics Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

United Therapeutics Corporation operates in Biotechnology & Specialty Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology & Specialty Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about United Therapeutics Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare United Therapeutics Corporation and its top competitor on Cyborg Score”
“What did United Therapeutics Corporation do this quarter?”
“Is United Therapeutics Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does United Therapeutics Corporation do?+
United Therapeutics is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. The company seeks to develop treatments for rare...
What is United Therapeutics Corporation's Cyborg Score?+
United Therapeutics Corporation has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are United Therapeutics Corporation's main competitors?+
Named competitors include Pulmonary Hypertension Therapies, Revatio, Adcirca (tadalafil), Organ Transplant Technologies. The full competitive landscape is in the AskCyborg report.
How can I get the full United Therapeutics Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the United Therapeutics Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track United Therapeutics Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology & Specialty Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8United Therapeutics Corporation